<h3>享受 TipRanks 高级版 50% 折扣，放心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>Arcturus Therapeutics (ARCT) 的最新动态现已发布。</p>
<p>2025 年 12 月 11 日，Arcturus Therapeutics 宣布其首席财务官 Andy Sassine 将于 2025 年 12 月 31 日友好离职。此离职并非因与公司存在任何分歧，他将获得包括薪水、奖金资格和股票期权调整在内的离职补偿。自 2024 年 3 月以来担任公司控制官的 Joe Roberts 被任命为临时首席财务官和会计官。此过渡预计不会影响罗伯茨先生当前的薪酬结构。</p>
<p>(ARCT) 股票的最新分析师评级为持有，目标价为 7.00 美元。要查看 Arcturus Therapeutics 股票的完整分析师预测列表，请访问 ARCT 股票预测页面。</p>
<p><strong>Spark 对 ARCT 股票的看法</strong></p>
<p>根据 Spark，TipRanks 的人工智能分析师，ARCT 的评级为中性。</p>
<p>Arcturus Therapeutics 的整体股票评分主要受到其财务表现的影响，面临收入下降和持续亏损的挑战。技术分析显示出看跌趋势，估值指标因负收益而不佳。尽管在临床试验和合作方面有一些积极进展，但这些都被重大的财务和监管挑战所掩盖。</p>
<p>要查看 Spark 对 ARCT 股票的完整报告，请点击这里。</p>
<p><strong>关于 Arcturus Therapeutics 的更多信息</strong></p>
<p>Arcturus Therapeutics Holdings, Inc. 在生物技术行业运营，专注于开发创新的 RNA 药物以治疗各种疾病。</p>
<p><strong>平均交易量：</strong> 1,328,952</p>
<p><strong>技术情绪信号：</strong> 卖出</p>
<p><strong>当前市值：</strong> 2.12 亿美元</p>

ARCT

<p>Arcturus Therapeutics 宣布首席财务官 Andy Sassine 将于 2025 年 12 月 31 日离职，Joe Roberts 被任命为临时首席财务官。Sassine 的离职是友好的，并将获得遣散费。分析师对 ARCT 股票的评级为持有，目标价为 7.00 美元。尽管临床试验结果积极，但财务挑战依然存在，影响了股票表现</p>

<h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks 高级版 50% 折扣，放心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>An update from Arcturus Therapeutics ( (ARCT) ) is now available.</p>
<div class="lb-trans"><p>Arcturus Therapeutics (ARCT) 的最新动态现已发布。</p>
</div><p>On December 11, 2025, Arcturus Therapeutics announced the amicable departure of its Chief Financial Officer, Andy Sassine, effective December 31, 2025. His exit was not due to any disagreements with the company, and he will receive a severance package including salary, bonus eligibility, and stock option modifications. Joe Roberts, the company’s Controller since March 2024, was appointed as the interim principal financial officer and accounting officer. This transition is not expected to affect Mr. Roberts’ current compensation structure.</p>
<div class="lb-trans"><p>2025 年 12 月 11 日，Arcturus Therapeutics 宣布其首席财务官 Andy Sassine 将于 2025 年 12 月 31 日友好离职。此离职并非因与公司存在任何分歧，他将获得包括薪水、奖金资格和股票期权调整在内的离职补偿。自 2024 年 3 月以来担任公司控制官的 Joe Roberts 被任命为临时首席财务官和会计官。此过渡预计不会影响罗伯茨先生当前的薪酬结构。</p>
</div><p>The most recent analyst rating on (ARCT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Arcturus Therapeutics stock, see the ARCT Stock Forecast page.</p>
<div class="lb-trans"><p>(ARCT) 股票的最新分析师评级为持有，目标价为 7.00 美元。要查看 Arcturus Therapeutics 股票的完整分析师预测列表，请访问 ARCT 股票预测页面。</p>
</div><p><strong>Spark’s Take on ARCT Stock</strong></p>
<div class="lb-trans"><p><strong>Spark 对 ARCT 股票的看法</strong></p>
</div><p>According to Spark, TipRanks’ AI Analyst, ARCT is a Neutral.</p>
<div class="lb-trans"><p>根据 Spark，TipRanks 的人工智能分析师，ARCT 的评级为中性。</p>
</div><p>Arcturus Therapeutics’ overall stock score is primarily impacted by its financial performance, which is challenged by declining revenues and persistent losses. Technical analysis indicates a bearish trend, and valuation metrics are poor due to negative earnings. While there are some positive developments in clinical trials and partnerships, these are overshadowed by significant financial and regulatory challenges.</p>
<div class="lb-trans"><p>Arcturus Therapeutics 的整体股票评分主要受到其财务表现的影响，面临收入下降和持续亏损的挑战。技术分析显示出看跌趋势，估值指标因负收益而不佳。尽管在临床试验和合作方面有一些积极进展，但这些都被重大的财务和监管挑战所掩盖。</p>
</div><p>To see Spark’s full report on ARCT stock, click here.</p>
<div class="lb-trans"><p>要查看 Spark 对 ARCT 股票的完整报告，请点击这里。</p>
</div><p><strong>More about Arcturus Therapeutics</strong></p>
<div class="lb-trans"><p><strong>关于 Arcturus Therapeutics 的更多信息</strong></p>
</div><p>Arcturus Therapeutics Holdings, Inc. operates in the biotechnology industry, focusing on the development of innovative RNA medicines for the treatment of various diseases.</p>
<div class="lb-trans"><p>Arcturus Therapeutics Holdings, Inc. 在生物技术行业运营，专注于开发创新的 RNA 药物以治疗各种疾病。</p>
</div><p><strong>Average Trading Volume:</strong> 1,328,952</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 1,328,952</p>
</div><p><strong>Technical Sentiment Signal:</strong> Sell</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 卖出</p>
</div><p><strong>Current Market Cap:</strong> $212M</p>
<div class="lb-trans"><p><strong>当前市值：</strong> 2.12 亿美元</p>
</div>

Arcturus Therapeutics 宣布首席财务官离职及继任安排